Lenvatinib

Lenvatinib
Clinical data
Trade names	Lenvima, others
Other names	E7080
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lenvatinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L01EX08 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	85% (estimated)
Protein binding	98–99%
Metabolism	CYP3A4, aldehyde oxidase, non-enzymatic
Metabolites	Desmethyl-lenvatinib (M2) and others
Elimination half-life	28 hours
Excretion	~65% feces, 25% urine
Identifiers
	IUPAC name 4-[3-Chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide;
CAS Number	417716-92-8 ;
PubChem CID	9823820;
IUPHAR/BPS	7426;
DrugBank	DB09078 ;
ChemSpider	7999567 ;
UNII	EE083865G2;
KEGG	D09919 ; as salt: D09920 ;
ChEBI	CHEBI:85994 ;
ChEMBL	ChEMBL1289601 ;
CompTox Dashboard (EPA)	DTXSID50194605 ;
Chemical and physical data
Formula	C21H19ClN4O4
Molar mass	426.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C4CC4NC(=O)Nc3ccc(cc3Cl)Oc1ccnc(cc2OC)c1cc2C(=O)N;
	InChI InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) ; Key:WOSKHXYHFSIKNG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.^[4]